Bolt Biotherapeutics (BOLT) FCF Margin (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted FCF Margin of 30857.69% for Q1 2026, down 10680.36% sequentially from 286.24% in Q4 2025, and down 2976399.0% YoY from N/an in Q1 2025.
Bolt Biotherapeutics (BOLT) FCF Margin (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported FCF Margin for 7 years, with the latest figure at 30857.69% in Q1 2026.
- Quarterly FCF Margin fell 2976399.0% year-over-year to 30857.69% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 532.08% (up 106066.0% YoY) and the FY2025 annual result came in at 518.8%, up 27872.0% from the prior year.
- FCF Margin eased to 30857.69% in Q1 2026 per BOLT's latest filing, from 286.24% in the prior quarter.
- Over five years, FCF Margin peaked at 286.24% in Q4 2025 and troughed at 30857.69% in Q1 2026.
- A 5-year average of 2891.57% and a median of 1073.75% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2026: FCF Margin jumped 206880 bps in 2022, then slumped 2976399 bps in 2026.
- Over 5 years, FCF Margin stood at 1285.33% in 2022, then soared by 47 bps to 680.56% in 2023, then slumped by 80 bps to 1224.36% in 2024, then surged by 77 bps to 286.24% in 2025, then tumbled by 10680 bps to 30857.69% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 30857.69%, 286.24%, and 452.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Bolt Biotherapeutics | 5.48 Mn | 5.48 Mn | - | -130,800.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -130,800.00% |
| Mar 31, 2026 | -30,857.69% |
| Dec 31, 2025 | -286.24% |
| Sep 30, 2025 | -452.01% |
| Jun 30, 2025 | -531.98% |
| Mar 31, 2025 | -1,093.70% |
| Sep 30, 2024 | -1,224.36% |
| Jun 30, 2024 | -1,268.94% |
| Mar 31, 2024 | -317.61% |
| Dec 31, 2023 | -680.56% |
| Sep 30, 2023 | -669.07% |
| Jun 30, 2023 | -1,053.80% |
| Mar 31, 2023 | -1,283.95% |
| Dec 31, 2022 | -1,285.33% |
| Sep 30, 2022 | -671.69% |
| Jun 30, 2022 | -1,523.04% |
| Mar 31, 2022 | -3,065.07% |
| Dec 31, 2021 | -3,354.13% |
| Sep 30, 2021 | -2,625.27% |
| Jun 30, 2020 | -19,559.70% |